TickerFacts.

Zhengye Biotechnology Holding Ltd (ZYBT): R&D Expense

Annual figures by period end, from SEC filings.

18.01M CNY
Year ended 2025-12-31
+10.3%
3-year compound annual growth
2022-12-31: 13.42M CNY2023-12-31: 11.90M CNY2024-12-31: 12.79M CNY2025-12-31: 18.01M CNY18.01M CNY
2022-12-31 R&D Expense (CNY) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-3118.01M CNY+40.8%2026-04-28, From 2025-01-01
2024-12-3112.79M CNY+7.5%2026-04-28, From 2024-01-01
2023-12-3111.90M CNY-11.3%2026-04-28, From 2023-01-01
2022-12-3113.42M CNYn/a2025-07-03, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Zhengye Biotechnology Holding Ltd (ZYBT)2025-12-3118.01M CNY+40.8%
Yatsen Holding Ltd (YSG)2025-12-31137.30M CNY+25.6%

Compare ZYBT, YSG side by side · Screen every company in Pharmaceutical Preparations ↗